Pfizer Inc. Common Stock (PFE)
Stock · NYSE · Health Care
$29.57as of 10/16/2026
Price chart
Active signals
PFE Signal Track Record
How signals performed across all stocks →What PFE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | -0.7% | 48% | September 18, 2026 |
| Bollinger Band Breakout | 22 | -0.7% | 36% | August 19, 2026 |
| Bollinger Band Breakdown | 21 | +1.1% | 52% | June 18, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -0.4% | 47% | July 16, 2026 |
| Any 20-session window (baseline) | -0.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 75,000
- Website
- www.pfizer.com/
Fundamentals
- 1-day range
- $29.42$29.74
- Market cap
- $149.33B
- P/E (trailing)
- 39.08
- P/E (forward)
- 10.18
- EPS (trailing)
- $0.76
- Dividend yield
- 5.38%
- Beta
- 0.31
- Avg. volume
- 35.17M
- Ex-dividend date
- November 6, 2026
- Dividend pay date
- December 7, 2026
How Pfizer Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Pfizer Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midtermsbenzinga · 10/17/2026
- How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?Yahoo · 10/11/2026
- Pfizer And 2 Other Top AI Healthcare StocksYahoo · 10/10/2026
- Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Here’s Where the Stock Could Go By 2030Yahoo · 10/10/2026
- Is Pfizer (PFE) Overvalued Even After Its Oncology Progress?Yahoo · 10/10/2026
- How Much More Dividend Income a Roth IRA Keeps on a Half-Million-Dollar PortfolioYahoo · 10/10/2026
- CDs vs. Dividend Stocks: The Income Gap Could Be Bigger Than Retirees ThinkYahoo · 10/10/2026
- $12,300 a Month in Dividends and Not One Bond: Is This Portfolio Too Good to Be True?Yahoo · 10/10/2026
- Why Is Everyone Ignoring Gilead Stock's High Cash Yield?Yahoo · 10/10/2026
Insider Activity
Insider Actions →- Albert Bourla · September 30, 2026 · Grant21 @ $28.52
- Mortimer J. Buckley · September 25, 2026 · Grant1.3K @ $28.67
- Joseph Echevarria · September 25, 2026 · Grant1.6K @ $28.67
- SMITH JAMES C · September 25, 2026 · Grant1.6K @ $28.67
- James Quincey · September 25, 2026 · Grant1.4K @ $28.67
- Taraporevala Cyrus · September 25, 2026 · Grant1.3K @ $28.67
- Shantanu Narayen · September 25, 2026 · Grant1.7K @ $28.67
- Albert Bourla · September 15, 2026 · Grant22 @ $27.55
- Albert Bourla · August 31, 2026 · Grant21 @ $28.46
- Albert Bourla · August 14, 2026 · Grant22 @ $26.79
- Albert Bourla · August 12, 2026 · Buy38.0K @ $26.34
- Jennifer B. Damico · August 5, 2026 · Sale3.3K @ $25.4
- Mortimer J. Buckley · August 5, 2026 · Buy37.6K @ $25.52
- Ronald E. Blaylock · August 5, 2026 · Buy39.2K @ $25.46
- Albert Bourla · July 31, 2026 · Grant24 @ $25.01
Institutional Ownership
March 31, 2026
- Total shares held
- 3.72B
- Total value held
- $100.55B
- Institutional holders
- 2920
- Unknown498.26M
- Unknown369.43M
- Unknown301.59M
- Unknown133.56M
- Unknown104.96M
- Unknown92.69M
- Unknown62.03M
- Unknown56.91M
- Unknown54.51M
- Unknown53.88M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff
Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.
Pfizer Declares 352nd Straight Dividend, Holds Steady Amid Vaccine Selloff. Pfizer announced its 352nd consecutive quarterly dividend, keeping a yield of about 5.4%. The company’s share price has stayed flat even as other vaccine makers like Novavax and Moderna fell. A new approval for the drug Tukysa could alter the company’s outlook, and analysts are watching the upcoming Q3 2026 earnings report for more detail.